Journals / Şişli Etfal Hastanesi Tıp Bülteni / 2018 / Cilt: 52 - Sayı: 4

Evaluation of Comorbidities in Patients with Autoimmune Bullous Diseases: A Retrospective Study

Pages
302–306
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We believe that it is important to evaluate accompanying diseases in patients with ABD.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: The purpose of the present study was to define the accompanying diseases of patients with autoimmune bullousdiseases (ABDs).Methods: One hundred forty-two patients with ABD who were followed up in the dermatology and venereology inpatient clinicof Şişli Hamidiye Etfal Training and Research Hospital between January 1999 and December 2015 were enrolled in the study.
📊
Key Findings & Data:Age,gender, and accompanying diseases of the participants were recorded and compared with the healthy subjects.Results: Eighty patients with pemphigus, 62 patients with pemphigoid, and 217 healthy subjects were included in the study.
💡
Conclusion & Impact:We believe that it is important to evaluate accompanying diseases in patients with ABD.
🔬Design:Research Article
📍Scope:2015 Verileri
⚙️Variables:Domain Parameters

Özet

Objectives: The purpose of the present study was to define the accompanying diseases of patients with autoimmune bullousdiseases (ABDs).Methods: One hundred forty-two patients with ABD who were followed up in the dermatology and venereology inpatient clinicof Şişli Hamidiye Etfal Training and Research Hospital between January 1999 and December 2015 were enrolled in the study. Age,gender, and accompanying diseases of the participants were recorded and compared with the healthy subjects.Results: Eighty patients with pemphigus, 62 patients with pemphigoid, and 217 healthy subjects were included in the study. Thepemphigoid group had a statistically significant higher prevalence of hypertension, diabetes mellitus, coronary artery diseases,cataract, malignancy, dementia, Alzheimer’s disease, Parkinson’s disease, and cerebrovascular events relative to the pemphigusand control groups (p<0.01, p<0.01, p=0.001, p<0.01, p=0.02, p=0.008, p=0.001, p=0.001, and p<0.01, respectively). The prevalenceof asthma, benign prostatic hyperplasia, and cataract was higher in the pemphigus group than in the controls (p=0.02,p=0.04, and p=0.02, respectively).Conclusion: To the best of our knowledge, this is the first study comparing accompanying diseases between controls and patientswith pemphigus and pemphigoid. It is disputable whether the diseases mentioned occur due to some common pathophysiologicalpathways or coexist just coincidentally. We believe that it is important to evaluate accompanying diseases in patients with ABD.

🔖

Cite This Article

KARABAY, E. A., ÇERMAN, A. A., ALTUNAY, K. İ. (2018). Evaluation of Comorbidities in Patients with Autoimmune Bullous Diseases: A Retrospective Study. Şişli Etfal Hastanesi Tıp Bülteni, Cilt: 52 - Sayı: 4, 302–306. https://ajindex.com/articles/364190

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Gül Ü, Kılıç A, Çakmak SK, Soylu S, Gönül M. Clinical and demographical features of autoimmune bullous diseases: A retrospective analysis of 85 analysis. Turkderm 2014;48:7–12
  2. Amagai M. Pemphigus. In: Bologna JL, Jorizzo JL, Rapini RP, editors. Dematology. 2nd ed. London: Mosby; 2008. p. 417–29
  3. Küçükoğlu R, Babuna G. The clinical diagnosis of autoimmune bullous diseases. Türkderm 2011;45:16–25
  4. Ljubojevic S, Lipozenčić J. Autoimmune bullous diseases associations. Clin Dermatol 2012;30:17–33
  5. Daneshpazhooh M, Chams-Davatchi C, Payandemehr P, Nassiri S, Valikhani M, Safai-Naraghi Z. Spectrum of autoimmune bullous diseases in Iran: a 10-year review. Int J Dermatol 2012;51:35–41
  6. Nanda A, Dvorak R, Al-Saeed K, Al-Sabah H, Alsaleh QA. Spectrum of autoimmune bullous diseases in Kuwait. Int J Dermatol 2004;43:876–81
  7. Uzun S, Durdu M, Akman A, Gunasti S, Uslular C, Memisoglu HR, et al. Pemphigus in the Mediterranean region of Turkey: a study of 148 cases. Int J Dermatol 2006;45:523–8
  8. Daye M, Mevlitoğlu İ, Esener S. Bullous disorders in Konya: A study of 93 cases. Türkderm 2013;47:200–4
  9. Akbaş A, Kılınç F, Akkuş A, Şener S, Metin A. A retrospective analysis of hospitalized autoimmune bullous disease patients. Dermatoz 2015;4:15064a1
  10. Uzun S. Pemphigus. In: Tüzün Y, Gürer MA, Serdaroğlu S, Oğuz O, Aksungur VL, editors. Dermatoloji. 3.baskı. İstanbul: Nobel Tıp Kitapeviİ 2008. p. 807–32
  11. Alpsoy E, Akman-Karakas A, Uzun S. Geographic variations in epidemiology of two autoimmune bullous diseases: pemphigus and bullous pemphigoid. Arch Dermatol Res 2015;307:291–8
  12. Demircioğlu D, Bükülmez G, Atakan N, Şahin S, Karaduman A, Akan T, et al. Pemfigus vulgarisli hatsaların klinik özellikleri ve tedaviye yanıtları: 6 yıllık Hacettepe deneyimi. Türkderm 2000;34:231–5
  13. Heelan K, Mahar AL, Walsh S, Shear NH. Pemphigus and associated comorbidities: a cross-sectional study. Clin Exp Dermatol 2015;40:593–9
  14. Michailidou EZ, Belazi MA, Markopoulos AK, Tsatsos MI, Mourellou ON, Antoniades DZ. Epidemiologic survey of pemphigus vulgaris with oral manifestations in northern Greece: retrospective study of 129 patients. Int J Dermatol 2007;46:356–61
  15. Teixeira VB, Cabral R, Brites MM, Vieira R, Figueiredo A. Bullous pemphigoid and comorbidities: a case-control study in Portuguese patients. An Bras Dermatol 2014;89:274–8
  16. Yeh SW, Ahmed B, Sami N, Razzaque Ahmed A. Blistering disorders: diagnosis and treatment. Dermatol Ther 2003;16:214